ESMO 2022

Reduction of peripheral neuropathy with taxane therapy

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Immuntherapy only for low risk patients?

DD is the champion!

Dose-dense therapy is beneficial for all patients

Endocrine response in eBC

Roadmap for the adjuvant setting

Simple and cheap surgical technique may impact survival in early breast cancer

My highlights of ESMO22

Consolidating data from prospective studies

QoL and longterm toxicity

Dose-dense standard of care is the optimal care

Long-term data on dose density therapy in chemotherapy

Dose dense is better

Il vincitore e’ il dose dense!!

Schéma dose-dense bénéfique pour toutes les patientes

Datele trialurilor se consolideata

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

I miei punti salienti di ESMO22

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Status update - adjuvant IO. Are TILs prognostic?

Unmeet needs and my wishes for 2022!

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Tailoring Adjuvant Therapy

How to deal with the negative SERD data?

Sacituzumab govitecan for everybody!

Update on biomarkers on ADCs of the DAISY trial

The third in the bunch

Discontinued development

Negative and yet positive?!

ADC after ADC - is there any orientation?

OS not significant, but re-assuring new data

CDK4/6i could be an option for selected ER+/HER2+ disease

SG is a novel treatment option for HR+/HER2- disease

My highlights of ESMO22

More therapy options for patients with HR+, HER2+ disease

Survival benefit from SG in mBC

VEX has no place in chemotherapy of metastatic breast cancer

Survival benefit in endocrine sensitive patients

Exciting data, but Phase 3 studies are needed

Interim analysis shows promising data on Abema in the 1st Line

HER2+ and still without chemotherapy

Another option for heavily pre-treated HR+ advanced breast cancer patients

New treatment option for heavily pre-treated patients with ER+ MBC

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

TROPiCS-02 highlights

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

Sopravvivenza globale nello studio MONARCH3

Survie globale pas encore significative statistiquement mais données rassurantes

Nouvelles données des analyses expolratoires dans l’étude DAISY

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

I miei punti salienti di ESMO22

Sacituzumab Govitecan: Un farmaco per tutte?

TROPiCS-02 highlights

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

ADAURA Update - preventing relapse or just delaying it?

Pollution and lung cancer - one mechanism revealed

INCREASE - to good to be true?

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Concurrent preoperative IO/CRT in early lung cancer

Is OS really needed?

ADAURA revisited

Long term follow-up of ADAURA trial

Osimertinib stays standard adjuvant

Neoadjuvant strategies for PD-L1 < 1 %

Osimertinib - curing or delaying relapse?

Window for treatment selection

Eine Plattform für "take the winner"-Strategie

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Osimertinib: una cura o ritarda la ripresa di malattia?

ADAURA revisited

Osimertinib bleibt Standard adjuvant

Pollution et cancer du poumon - un mécanisme mis en évidence

Langzeitdaten ADAURA

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

DFS matters!

Important data on borderline resectable patients

Can IO be discontinued?

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Sotorasib vs. Docetaxel in mKRAS G12C

5-year data on survival under immunotherapy

HER2 - the next actionable mutation in lung cancer?

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Immunotherapy in unfit population? Perhaps...

Sotorasib: sweet and sour results

A new step in treatment of KRAS G12C mutant NSCLC

Pneumonitis and T-DXd

Preview on lung cancer highlights

Emerging IO mono options in the first line

Real-world data on Atezolizumab

Cemiplimab beyond progression?

Chemoimmunotherapy - improvement of survival after 5 years

The journey at KRAS G12C continues

Can we finally treat poor prognostic patients with immunotherapy?

New immunotherapy options for pts. ineligible to 1st line platinum therapy

One more brick in the KRAS G12C wall

If you don't look, vou don't find - once you found it, you'll treat it!

5 years of chemoimmunotherapy: solid grounded

DESTINY-Lung02 - better than the original?

Liquid biopsy monitoring in treatment decisions

Question about timing and duration of immunotherapy still unanswered

Atezolizumab better than vinorelbin in reduced performance status

Is shorter immunotherapy equally effective and less physically demanding?

Poseidon and STK11/KEAP

5-year update on 1st line chemoimmunotherapy

New therapy combination after progression on 1L osimertinib

Induction chemoimmunotherapy in borderline resectability?

Sotorasib - a new standard of care?

Neue Option der IO-Therapie in der Erstlinie

Sotorasib vs. Docetaxel bei mKRAS G12C

IO-IO neoadjuvant bei PD-L1 neg.

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Poseidon und STK11/KEAP

Neue Therapiekombination in der Resistenz nach Osimertinib

Chimio-immunothérapie - amélioration de la survie après 5 ans

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

5-Jahresüberleben mit Immuntherapie

5 Jahre Chemo-Immuntherapie: starker Effekt

Liquid Biopsy Monitoring zur Therapiesteuerung

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Pneumonitis und T-DXd

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Immunoterapia nella popolazione non fit: forse

Données de vie réelle avec l’atezolizumab

Un mattone in piu' nel muro del KRAS G12C

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Les études incontournables à l’ESMO 2022

Atezo besser als Vino bei PS2-3

Die Reise bei KRAS G12C geht weiter

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Kann IO pausiert werden?

Resultados Agridulces de Sotorasib

Cemiplimab beyond progression?

New strategies in immunotherapy

Heterogenity in the genetic landscape - little progress in molecular alterations

A positive study! With a question mark?

Novel data and long-term efficacy of chemo-IO in mNSCLC

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

No value of IPI/Nivo in the adjuvant setting.

Two negative studies question adjuvant approach in RCC

Adjuvant Immuntherapy in kidney cancer

Brief highlights about RCC & urothelial cancer from ESMO22

New combo - triplet therapy for kidney cancer

Place of triplet therapy

News in terms of adjuvant

More questions being raised

Exciting data for high-risk patients: is this the start of a new era?

Immune-based peri-operative treatment in RCC: What went wrong?

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Inmunoterapia adyuvante en el cancer renales

Terapia triple para cancer renales

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

Shedding light on TKI/Checkpointinhibitor combinations

Therapy combinations in RCC - what is the role of triplet therapy?

Immunomodulation in combination with checkpointinhibiton

Brief highlights about RCC & urothelial cancer from ESMO22

EV + Pembro with excellent response rates

EV + pembrolizumab in cisplatin-ineligible patients

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Promising data, but beware of toxicity

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

In older vulnerable - less is more

Combination of olaparib leads to promising results

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

ADT + ENZA better choice than monotherapy

QoL data from ARASENS triplet therapy study mHRPC

Genetic testing before PARP therapy is useful

Cabazitaxel better tolerated in elderly men

Update on the PROpel study

IO + PARP without benefit in the allcomer situation

PSA at 8-months as a biomarker

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

Biomarker data for better patients selection

Length of hormone therapy after radiation

Radicals - ADT & Radiotherapy

Further evaluation of PSA correlates

Optimizing cabazitaxel chemotherapy

Triplet therapy with darolutamide in prostate cancer

ADCs - a possible therapeutic approach

Uppdatering i PROpel studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Livskvalitetsuppföljning i ARASENS studien

Intimate partner violence in cancer patients

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

Addition of CPI to Radiochemotherapy in LA-HNSCC?

TILs - Fashion is the eternal return of the old

New group of substances for rare diseases

Novel approach von Biontech towards Cancer – game changing potential?!